Francois Vergez
Overview
Explore the profile of Francois Vergez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
1499
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bertoli S, Berard E, Peterlin P, Guieze R, Desbrosses Y, Hicheri Y, et al.
Haematologica
. 2025 Feb;
PMID: 39911128
Not available.
2.
Recher C, Dumas P, Berard E, Tavitian S, Leguay T, Galtier J, et al.
Am J Hematol
. 2024 Nov;
100(1):23-32.
PMID: 39555737
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of...
3.
Jeanselme P, Tavitian S, Lapierre L, Vergez F, Rigolot L, Huynh A, et al.
Leuk Lymphoma
. 2024 Aug;
65(13):2025-2030.
PMID: 39141583
Adult T-cell acute lymphoblastic leukemia has a poor outcome after relapse. Because the subtype of early T-cell precursor displays characteristics close of those of acute myeloid leukemia, such as epigenetic...
4.
Larrue C, Mouche S, Angelino P, Sajot M, Birsen R, Kosmider O, et al.
Sci Transl Med
. 2024 Jul;
16(757):eadk1731.
PMID: 39047119
Acute myeloid leukemia (AML) remains a challenging hematological malignancy with poor prognosis and limited treatment options. Leukemic stem cells (LSCs) contribute to therapeutic failure, relapse, and adverse outcome. This study...
5.
Garciaz S, Dumas P, Bertoli S, Sallman D, Decroocq J, Belhabri A, et al.
Am J Hematol
. 2024 Jun;
99(10):1870-1876.
PMID: 38899566
Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration...
6.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al.
Nat Med
. 2024 Jun;
30(8):2235-2241.
PMID: 38830994
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of...
7.
Gondran C, Dumas P, Berard E, Bidet A, Delabesse E, Tavitian S, et al.
Blood Cancer J
. 2024 May;
14(1):91.
PMID: 38821940
Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/BCR::ABL1, a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification....
8.
Dussiau C, Comont T, Knosp C, Vergnolle I, Bravetti C, Canali A, et al.
Leukemia
. 2024 Apr;
38(5):1131-1142.
PMID: 38575672
Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the compartment of hematopoietic stem and progenitors cells (HSPCs), leading in some cases to leukemic transformation. We hypothesized that deciphering...
9.
Chea M, Rigolot L, Canali A, Vergez F
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38396825
Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and...
10.
Didi I, Alliot J, Dumas P, Vergez F, Tavitian S, Largeaud L, et al.
Leuk Res
. 2024 Jan;
136:107437.
PMID: 38215555
We designed artificial intelligence-based prediction models (AIPM) using 52 diagnostic variables from 3687 patients included in the DATAML registry treated with intensive chemotherapy (IC, N = 3030) or azacitidine (AZA,...